Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 28, 2021; 27(32): 5376-5391
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5376
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5376
Figure 1 Histopathological changes of inhibitor-related hepatotoxicity.
A: Prominent perivenulitis (black arrow) with endothelialitis (orange arrow) in a case of ipilimumab related hepatotoxicity (hematoxylin and eosin, 400 ×); B: Lymphocytic cholangitis with prominent duct damage secondary to nivolumab (black arrows; hematoxylin and eosin, 400 ×).
- Citation: Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol 2021; 27(32): 5376-5391
- URL: https://www.wjgnet.com/1007-9327/full/v27/i32/5376.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i32.5376